These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-001984-22 Essai randomisé de phase III comparant l’association traitement hormonal + docétaxel au traitement hormonal seul dans les cancers de la prostate métastatiques not-yet-due
Ongoing 2004-002839-10 Phase II trial assessing the impact on instrumental and daily living autonomy of a chemotherapy regimen with bi-weekly docetaxel in the treatment of metastatic breast cancer in patients over the age o... not-yet-due
Not reported 2005-001072-13 A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206 2012-05-14 due-trials
Ongoing 2006-003336-30 Essai de phase II multicentrique étudiant l’impact de la séquence thérapeutique radiochimiothérapie pré opératoire (50 Gy + capecitabine + oxaliplatine + cetuximab) suivie d’une chirurgie TME puis d’u... not-yet-due
Ongoing 2006-003377-27 Etude Intergroupe (SFCE/GSF/GETO) OS2006 Zolédronate-Ostéosarcome Protocole de traitement des ostéosarcomes de l’enfant, de l’adolescent et de l’adulte comportant : - un essai randomisé - et des étud... not-yet-due
Ongoing 2006-006175-20 Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose péritonéale d'origine colorectale associée à une chimioth... not-yet-due
Ongoing 2006-006409-10 Étude multicentrique de phase II randomisée, évaluant l’efficacité de l’anastrozole et du fulvestrant dans le traitement néo-adjuvant du cancer du sein opérable chez les femmes ménopausées et ayant po... not-yet-due
Ongoing 2006-006494-24 Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast c... not-yet-due
Ongoing 2007-000687-24 Prévention du cancer du sein par le létrozole chez la femme ménopausée porteuse d'une mutation brca 1/2 not-yet-due
Ongoing 2007-002495-34 Etude randomisée multicentrique comparant une radiothérapie adjuvante immédidate associée à une hormonothérapie courte par analogue LH-RH (Décapeptyl LP®) vs une radiothérapie différée à la rechute b... not-yet-due
Ongoing 2007-004098-24 A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery not-yet-due
Ongoing 2007-007029-38 Essai de phase II multicentrique non randomisée étudiant l’impact de l’association radiochimiothérapie (65 Gy + cisplatine + 5FU) au cetuximab chez les patients présentant un cancer anal localement av... not-yet-due
Ongoing 2008-001084-10 A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. not-yet-due
Ongoing 2008-004560-39 Essai de phase III multicentrique randomisé, comparant l’effet d’une chimiothérapie adjuvante de 6 mois par gemcitabine-oxaliplatine à 85mg/m² (GEMOX 85) à une surveillance, chez des patients opérés ... not-yet-due
Ongoing 2008-008167-99 Etude randomisée de phase III comparant l’Exemestane à un placebo chez des femmes ménopausées à risque élevé de cancer du sein. not-yet-due
Ongoing 2009-011882-10 Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutat... not-yet-due
Ongoing 2009-012813-22 Essai de phase II, randomisé multicentrique, évaluant le meilleur protocole de chimiothérapie associée à une thérapie ciblée choisie selon le statut KRAS dans les métastases hépatiques initialement no... not-yet-due
Ongoing 2009-012942-22 Essai de phase II, randomisé multicentrique, évaluant l'efficacité d'une chimiothérapie standard à base de fluoropyrimidine associée au cétuximab ou au bévacizumab, chez des patients kras sauvage, att... not-yet-due
Ongoing 2009-015981-73 Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2 not-yet-due
Ongoing 2009-017092-24 Etude de phase II randomisée d’évaluation de la faisabilité d’une chimiothérapie par docetaxel prednisone sur un mode hebdomadaire ou toutes les 3 semaines dans une population de patients âgés (+75ans... not-yet-due
Ongoing 2010-022037-29 Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recu... not-yet-due
Ongoing 2010-023035-42 Randomized phase III study evaluating hyperthermic intraperitoneal not-yet-due
Not reported 2010-024046-29 Etude de phase II, randomisée, multicentrique, de l’Afatinib (BIBW2992) administré en pré-opératoire, chez des patients ayant un carcinome épidermoïde des voies aérodigestives supérieures non métastat... 2016-01-06 due-trials
Ongoing 2011-004744-22 Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine tr... not-yet-due
Other 2012-000142-35 A prospective randomised phase III study of androgen deprivation therapy (+/- docetaxel) with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastat... not-yet-due
Ongoing 2012-000566-38 A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse not-yet-due
Ongoing 2012-001561-32 Etude de phase II randomisée multicentrique comparant l'efficacité d'une hormonothérapie courte concomitante à une radiothérapie versus une radiothérapie exclusive dans le traitement de rattrapage de ... not-yet-due
Completed, but no date 2012-002525-29 A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer. bad-data
Ongoing 2012-002556-17 A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast ... not-yet-due
Ongoing 2012-003187-44 Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breas... not-yet-due
Ongoing 2013-000885-13 Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug not-yet-due
Ongoing 2013-001653-27 Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer not-yet-due
Ongoing 2013-003910-42 A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas. not-yet-due
Ongoing 2014-001225-33 Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. not-yet-due
Ongoing 2014-002560-33 Open-label, randomized, multicenter, international, parallel exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of sta... not-yet-due
Ongoing 2014-003510-82 _ not-yet-due
Ongoing 2015-000580-14 A single arm, open-label, phase II study to assess the efficacy of rucaparib in metastatic breast cancer patients with a BRCAness genomic signature. not-yet-due
Ongoing 2015-004340-19 Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) harboring a ... not-yet-due
Ongoing 2016-000764-42 A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4... not-yet-due
Ongoing 2016-001490-33 Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis. not-yet-due
Ongoing 2016-001491-29 A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting not-yet-due
Ongoing 2016-002257-37 Secured access to nivolumab for adult patients with selected rare cancer types not-yet-due
Ongoing 2016-002260-14 Secured access to pembrolizumab for adult patients with selected rare cancer types. not-yet-due
Ongoing 2016-004360-18 Randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in estrog... not-yet-due
Ongoing 2017-001165-24 A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis ... not-yet-due
Ongoing 2017-002284-18 A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine not-yet-due
Ongoing 2017-002320-25 Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS. not-yet-due
Ongoing 2017-004512-19 An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-mus... not-yet-due
Ongoing 2018-001807-35 Phase II study of maintenance anti-PD-L1 treatment with atezolizumab after chemo-radiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing not-yet-due